Brokerage Reports: Jefferies on Reliance Industries: Buy, Target Rs 1700, JPMorgan on ER&D: KPIT Tech, Persistent, Tata Elxsi, Kotak on Emcure: Buy, Target Rs 1680, Citi on L&T Finance: Buy, Target Rs 221

Brokerage Reports: Jefferies on Reliance Industries: Buy, Target Rs 1700, JPMorgan on ER&D: KPIT Tech, Persistent, Tata Elxsi, Kotak on Emcure: Buy, Target Rs 1680, Citi on L&T Finance: Buy, Target Rs 221

Jefferies on Reliance

Rating: Maintain Buy with a target price of Rs 1700.

Outlook: The risk-to-reward for Reliance is compelling.

Refining: Expect a year-on-year improvement in Singapore Gross Refining Margins (SGP GRM) in CY25, as the supply-demand situation in refining becomes more favorable.

Jio: Jio’s strong growth in home broadband subscribers positions it well for 5G monetization.

Public Listing: Likely to see a public listing in CY25.

Retail: Retail performed well in October, but a sustained recovery could take up to two quarters.

Valuation: The current valuation implies a $57 billion valuation for Retail, which Jefferies considers pessimistic.

JPMorgan on ER&D Services

Overview: The growth premium for ER&D services compared to IT has decreased, but it’s expected to increase again next year.

Auto Sector: The weakness in the automotive sector is seen as temporary, and growth is expected to pick up next year.

Telecom: The ER&D sector’s premium will not return to previous highs due to ongoing challenges in the telecom sector.

Preferred Stocks:

KPIT Tech: Maintain Overweight with a target price of Rs 1900.

Persistent: Maintain Overweight with a target price of Rs 6100.

L&T Tech: Maintain Overweight with a target price of Rs 6300.

Cyient: Maintain Overweight with a target price of Rs 2250.

Tata Elxsi: Maintain Underweight with a target price of Rs 6400.

Tata Tech: Maintain Underweight with a target price of Rs 800.

Jefferies on Real Estate

Residential Markets: The real estate market had a strong start to the busy season, with sales in October reaching a 6-month high.

Sales Trends: Value sales are up more than 20% due to a better mix of products and pricing.

Future Outlook: Many large new launches are expected in the second half of the year, which will likely lead to strong sales.

Growth: Listed developers are expected to see pre-sales growth of around 25% for FY25, even though Q2 was weak.

Stock Picks: Prefer stocks such as Godrej Properties, Lodha, and DLF.

JPMorgan on Defence

BEL: Initiate Overweight with a target price of Rs 340.

Hindustan Aeronautics: Initiate Overweight with a target price of Rs 5135.

Mazagon Dock: Initiate Neutral with a target price of Rs 4248.

Growth Prospects: The defence sector has strong growth potential, and recent stock price corrections are seen as a buying opportunity.

Key Pick: BEL is seen as the best option for exposure to long-term growth in defence production and exports.

Kotak Securities on Emcure

Rating: Upgrade to Buy from Add, with a target price of Rs 1680.

Growth Outlook: Emcure’s organic growth is expected to improve in the second half of the year, especially due to new licensing deals with Sanofi and the consolidation of Mantra.

EPS Growth: The company is expected to see a 29% compound annual growth rate (CAGR) in EPS, driven by higher utilization, lower interest costs, and more positive outcomes.

JPMorgan on Bharti Hexacom

Rating: Maintain Overweight with a target price of Rs 1630.

Business Model: The ‘social’ impact of the business model is often overlooked.

Financial Performance: The company continues to have top operational and financial metrics.

Network Expansion: Bharti’s network expansion is not only growing its social reach but also boosting market share.

ESG: Bharti’s environmental, social, and governance (ESG) efforts are potentially underappreciated in the market.

UBS on Swiggy

Rating: Initiate Buy with a target price of Rs 515.

Growth Potential: Swiggy is well-positioned for growth, currently trading at a 35% discount compared to Zomato.

Online Food Delivery: Swiggy’s margins and scale are catching up to Zomato’s, with similar GMV (Gross Merchandise Value) growth expected from FY24-27.

Goldman Sachs on Sun Pharma

Rating: Sell with a target price of Rs 1600.

R&D and Cost Outlook: Sun Pharma has reduced its R&D guidance to 7-8% of sales due to delays in the GL0034 clinical trials, which are now expected to push into FY26.

Jefferies on Real Estate

Market Update: Residential markets saw a festive boost in October, with sales reaching a 6-month high.

Sales Growth: Value sales grew by 20%+, aided by better product mix and pricing.

Outlook: Expect good sales to help listed developers post 25% pre-sales growth for FY25.

Stock Picks: Prefer Godrej Properties, Lodha, and DLF.

Citi on L&T Finance

Rating: Buy with a target price of Rs 221.

Growth Plans: L&T Finance aims to double its book size in the next 3-4 years, expecting a 20-25% CAGR in AUM (Assets Under Management).

Credit Costs: The credit cost is expected to stabilize between 2.0-2.25%, supporting a steady return on assets (ROA) of 2.8-3.0%, despite a reduction in MFI (Microfinance) exposure.

Leave a Reply

Your email address will not be published. Required fields are marked *